"Small Clip" Closes the "Heart Gate": A Cardiovascular Center Successfully Completed a Difficult Transcatheter Mitral Valve Clamping Operation

Link of the original article:https://mp.weixin.qq.com/s/OUBXj6oITCErMjxp-cQCUw

Mitral regurgitation refers to the failure of the one-way valve between the left ventricle and the left atrium of the heart to close, which is similar to the failure of the "heart valve", causing blood to flow backwards from the left ventricle into the left atrium, potentially causing serious consequences such as heart enlargement and heart failure.

Recently, Shanghai General Hospital Cardiovascular Disease Clinical Medical Center with the support of Prof.Wenyi Yang, Director of Coronary Heart Disease and Structural Cardiology cooperated Anesthesia Department, Cardiac Color Doppler Ultrasound Room, Cardiac Catheter Room and other teams to carry out an internationally advanced high difficulty transcatheter mitral valve clipping (MitraClip) on a patient with post-myocardial infarction heart failure accompanied by severe mitral regurgitation..

The operation involves minimally invasive intervention through the femoral vein,using the gripper to tightly close the "cardiac valve" in the patient's position with mitral regurgitation to reduce mitral regurgitation. It features low trauma and high safety and can greatly improve the patient's quality of life and life expectancy.

"After a heart attack, Mr. Jin, 74, repeatedly suffered from heart failure. Recently, he came to the Cardiovascular Clinical Medical Center of Shanghai General Hospital for hospitalization. After receiving intensive and standard medication from the team of Prof. Hongli Li and Wen Qinzhu in the cardiac care unit, Mr. Jin still repeatedly experienced leaking pleural effusion.". Cardiac ultrasound color Doppler examination showed that Mr. Jin's heart had "severe mitral regurgitation.".

Generally speaking, mitral valve replacement or valvuloplasty through thoracotomy is the preferred surgical method for mitral regurgitation. However, for older patients such as Mr. Jin who have poor cardiopulmonary function, the risk of thoracotomy is high.

With the support of Prof. Shaowen Liu, director of the Clinical Medical Center for Cardiovascular Diseases and the Department of Coronary Heart Disease and Structural Heart Disease, Prof. Wenyi Yang, led the structural heart valve team to carefully analyze Mr. Jin's condition, and finally decided to perform the internationally advanced minimally invasive interventional surgery for the patient - "Mitra Clip".

On the day of the surgery, Prof. Yang led the team to closely cooperate with Prof. Jinbao Li, the director of anesthesia department, the cardiac color ultrasound room, and the cardiac catheterization room to complete the MitraClip operation. The postoperative examination results showed that Mr. Jin's mitral regurgitation decreased from the fourth grade before the operation to a slight level after the operation, and his cardiac function improved significantly. At the same time, minimally invasive surgery has also accelerated the postoperative recovery of patients, and Mr.Jin can move around the next day for activities.

It has been reported that there are currently about 10 million patients with primary and secondary severe mitral regurgitation in China, whose life and health are constantly threatened by complications such as cardiac enlargement and heart failure caused by it. Transcatheter interventional therapy for mitral regurgitation features less trauma, shorter surgical time, and higher safety. It is more suitable for elderly patients with mitral regurgitation who have a history of thoracotomy, poor cardiac function, or multiple organ dysfunction. The MitraClip system used by the Coronary Heart Disease and Structural Cardiology Department of the Cardiovascular Clinical Medical Center of Shanghai General Hospital is currently a relatively mature transcatheter mitral valve rim repair device in the world, and is also the first device of the same type that has been approved by EU CE, US FDA, and China's Drug Administration.

The Cardiovascular Clinical Medical Center of Shanghai General Hospital is a member unit of the Shanghai Heart Valve Disease Intervention Center Alliance. The Coronary Heart Disease and Structural Cardiology Department team under the center, in addition to routine operations such as congenital heart disease, patent foramen ovale, and left atrial appendage interventional occlusion, has also successively performed transcatheter aortic valve replacement (TAVR), transcatheter aortic valve, and mitral perivalvular fistula occlusion under the leadership of specialist director Yang Wenyi Mitral valve clipping. With the help of the construction platform of a high-level comprehensive hospital and the strength of a nationally certified cardiovascular center, our team in the Department of Coronary Heart Disease and Structural Cardiology will continue to actively carry out various "high precision and cutting-edge" minimally invasive surgery to protect the lives and health of patients with heart disease.

Correspondent/Cardiovascular Clinical Medical Center Li Ya

Publicity Department Populus euphratica

Editor/Publicity Department Cai Shishi